Packaging systems for human recombinant adenovirus to be used in gene therapy
Patent 6878549 Issued on April 12, 2005. Estimated Expiration Date: June 14, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
435/463, Involving general or homologous recombination (e.g., gene targeting, etc.)435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)435/455, Introduction of a polynucleotide molecule into or rearrangement of nucleic acid within an animal cell435/456, The polynucleotide is encapsidated within a virus or viral coat435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/91.4Modification or preparation of a recombinant DNA vector
Methods and corresponding compounds for generating adenoviral vectors. One such method entails a method for generating an adenoviral vector comprising welding together two nucleic acid molecules wherein the molecules comprise partially overlapping sequences capable of combining with each other allowing the generation of a physically linked nucleic acid comprising at least two functional adenovirus inverted terminal repeats, a functional encapsulation signal and a nucleic acid of interest or functional parts, derivatives and/or analogues thereof. Further disclosed are nucleic acid molecules for generating adenoviral vectors.
Other References
K. L. Berkner, Expression of Heterologous Sequences in Adenoviral Vectors, Current Topics in Microbiology and Immunology, vol. 158, Springer-Verlag Berlin Heidelberg 1992.*
Leslie Stratford-Perricaudet et al, Gene transfer into animals: the promise of adenovirus, Human Gene Transfer, 1991, vol. 219, pp. 51-61.*
Amalfitano et al., “Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors”, Proc. Natl. Acad. Sci. USA, 93:3352-3356, Apr. 1996.
Amalfitano et al., “Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy”, Gene Therapy, 4:258-263, 1997.
Armentano et al., “Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion”, Human Gene Therapy, 6:1343-1353, Oct. 1995.
Blase et al., Vectors in Cancer therapy: how will they delier?, Cancer Gene Therapy, vol. 2, No. 4, 1995, pp. 291-297.
Bout et al., “In vivo adenovirus-mediated transfer of human CFTR cDNA to Rhesus monkey airway epithelium: efficacy, toxicity and safety”, Gene Therapy 1, pp. 385-394, 1994.
Bout et al., “Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium”, Human Gene Therapy, 5:3-10, 1994.
Brough et al., “A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4”, Journal of Virology, 70(9):6497-6501, Sep. 1996.
Brough et al., Stable Cell Lines for Complementation of Adenovirus Early Regions E1, E2A and E4; Abstract Book CSH Conference On Gene Therapy, 42, 1996.
Brough et al., “Construction, Characterization, and Utilization of Cell Lines Which Inducibly Express the Adenovirus DNA-Binding Protein”, Virology, 190:624-634, 1992.
Caravokyri et al., “Constitutive Episomal Expression of Polypeptide IX (pIX) in a 293-Based Cell Line Complements the Deficiency of pIX Mutant Adenovirus Type 5”, Journal of Virology, 69 (11):6627-6633, Nov. 1995.
Fallaux et al., “Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral Vectors”, Human Gene Therapy, 7:215-222, 1996.
Fallaux et al., “New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adeoviruses”, Human Gene Therapy, 9:1909-1917, Sep. 1, 1998.
Fisher et al., “Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis”, Virology, 217:11-22, 1996.
Gao et al., “Biology of Adenovirus Vectors with E1 and E4 Deletions for Liver-Directed Gene Therapy”, Journal of Virology, 70(12):8934-8943, Dec. 1996.
Gorziglia et al., “Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy”, Journal of Virology, 70 (6):4173-4178, Jun. 1996.
Haddada et al., “Adenoviral Interleukin-2 Gene Transfer into P815 Tumor Cells Abrogates Tumorigenicity and Induces Antitumoral Immunity in Mice”, Human Gene Therapy, 4:703-711, 1993.
Hardy et al., “Construction of Adenovirus Vectors through Cre-Iox Recombination”, Journal of Virology, 71 (3):1842-1849, Mar. 1997.
Hahir et al., “Molecular Characterization of Replication-Competent Variants of Adenovirus Vectors and Genome Modifications To Prevent Their Occurrence”, Journal of Virology, 70 (12):8459-8467, Dec. 1996.
Imler et al., “Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors”, Gene Therapy, 3:75-84, 1996.
Kornberg, Arthur, “DNA Replication”, W.H. Freeman and Company, San Francisco, 8 pages.
Krougliak et al., “Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants”, Human Gene Therapy, 6:1575-1586, Dec. 1995.
Lieber et al., “Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo”, Journal of Virology, 70:8944-8960, Dec. 1996.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problem and Tertiary Structure Prediction, 5 pages.
Sabatie et al., “Process Development for the Production of Second Generation Adenovirus Vectors for Gene Transfer in Clinical Protocols”, Abstract Book 14th Meeting on Animal Cell Technology, BI-3, 1996.
Schaack et al., “Adenovirus Type 5 Precursor Terminal Protein-Expressing 293 and HeLa Cell Lines”, Journal of Virology, 69 (7):4079-4085, Jul.1995.
Vanhaesebroeck et al., Virology, 176(2), pp. 362-368, Jun. 1990.
Vincent et al., “Herpes Simplex Virus Thymidine Kinase Gene Therapy for Rat Malignant Brain Tumors”, Human Gene Therapy 7:197-205, Jan. 20, 1996.
Vincent et al., “Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene”, J. Neurosurg., vol. 85, pp. 648-654, 1996.
Wang et al., “A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions”, Gene Therapy, 2:775-783, 1995.
Yeh et al., “Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions from a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit”, Journal of Virology, 70(1):559-565, Jan. 1996.
Zhou et al., “Development of a Complementing Cell Line and a System for Construction of Adenovirus Vectors with E1 and E2a Deleted”, Journal of Virology, 70(1):7030-7038, Oct. 1996.
June 14, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
